tbuckley/cabot-search huggingface dataset:
ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.
Authors: Christian Marth, Christof Vulsteke, Maria Jesus Rubio Pérez, Vicky Makker, Elena Ioana Braicu, Iain A. McNeish, Radoslaw Madry, Ali Ayhan, Kosei Hasegawa, Xiaohua Wu, Lea Dutta, Cindy Xu, Stephen Michael Keefe, John J. Lee, Sandro Pignata
Journal: Journal of Clinical Oncology (2020)

TPS6106 Background: The prognosis for endometrial cancer (EC) can be favorable when diagnosed in early stages, but prognosis and overall survival are poor in patients with advanced or recurrent EC. First-line standard of care for patients with advanced or recurrent EC is paclitaxel and carboplatin chemotherapy; however, there is a need for more effective and tolerable therapies. In the phase Ib/II trial KEYNOTE-146, which assessed the PD-1 inhibitor pembrolizumab (pembro) in combination with the multikinase inhibitor lenvatinib, an objective response rate (ORR) of 38% was observed (N=108) in patients with previously treated advanced EC. ENGOT-en9/LEAP-001 (NCT03884101) is a randomized, open-label, active-controlled, phase III study investigating pembro + lenvatinib vs chemotherapy in patients with newly diagnosed advanced or recurrent EC. Methods: Patients with newly diagnosed advanced (stage III-IV) or recurrent EC not previously treated with antiangiogenic agents; systemic chemotherapy (unless within a chemoradiation regimen); PD-1, PD-L1, or PD-L2 inhibitors; or other T-cell receptor–targeted therapies will be eligible. Patients will be randomized 1:1 to receive pembro 200 mg every 3 wk (Q3W) + lenvatinib 20 mg daily or paclitaxel 175 mg/m 2 Q3W + carboplatin AUC 6 Q3W. Randomization will be stratified on the basis of proficient vs deficient mismatch repair (pMMR vs dMMR) status. The pMMR population will be further stratified by prior chemoradiation (yes vs no), measurable disease (yes vs no), and ECOG performance status (0 vs. 1). Patients will continue on treatment for up to 35 cycles of pembro vs 7 cycles of chemotherapy or until initiation of a new anticancer treatment, unacceptable adverse events, or withdrawal of consent. Primary study endpoints are progression-free survival (per RECIST v1.1 by blinded independent central review) and overall survival. Secondary study endpoints are ORR, health-related quality of life, safety and tolerability, and lenvatinib pharmacokinetics. Exploratory endpoints will include disease control rate, clinical benefit rate, and duration of response. Enrollment is ongoing. Clinical trial information: NCT03884101.
Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (<i>MET</i><sup>Amp/Ex14∆</sup>).
Authors: D. Ross Camidge, Filip Janku, Alejandro Martinez-Bueno, Daniel V.T. Catenacci, Jeeyun Lee, Se-Hoon Lee, Afshin Dowlati, Kristoffer Staal Rohrberg, Alejandro Navarro, Yong Wha Moon, Mark M. Awad, Rebecca Suk Heist, Thomas Tuxen Poulsen, Arielle Yablonovitch, Lindsay Fosler, Helle Rudbaek, Frank Nygaard, Debra L. Wood, Rita P. Dalal, Enriqueta Felip
Journal: Journal of Clinical Oncology (2020)

9510 Background: Sym015, a mixture of 2 humanized antibodies, triggers MET degradation by a unique mechanism with superior specificity compared to tyrosine kinase inhibitors (TKIs). The Sym015-01 phase (P)1a trial met, the primary objective of identifying the recommended P2 dose (RP2D) as 18 mg/kg on cycle 1 day 1 followed by 12 mg/kg Q2W. The P2a was expanded to enroll MET Amp/Ex14 ∆ NSCLC patients (pts) based on preliminary efficacy findings. Here we present interim safety (n = 45) and efficacy (NSCLC cohort, n = 20) results from P2a. Methods: The expansion NSCLC Cohort enrolled pts with MET E x14Δ (n = 12) or MET Amp (n = 8 defined as &gt; 5 MET copies by NGS or MET/CEP7 ratio &gt; 2.2 updated to ≥3.0 by in situ hybridization; including 1 with MET Amp+Ex14Δ ). Tumor MET status was confirmed centrally and longitudinal ctDNA was analyzed by Guardant360. Results: By January 2020, 45 pts (median age 61.7 years) have been treated in P2a. Median duration of exposure (DoE) was 3.8 months (m) (n = 45; range 0.4+ to 22 m). Treatment emergent adverse events occurred in 93%, treatment related AEs (TRAE) in 42.2% and TRAE ≥G3 in 13.3% pts. No pts discontinued or died due to TRAE. The most common TRAE in ≥10% pts were fatigue (13.3%) and peripheral edema (11.1%). Of 20 NSCLC pts, 5 had confirmed PR (ORR 25%; 2/8 MET Amp and 3/12 MET Ex14Δ ); 11 had SD (DCR 80%; 6/8 MET Amp and 5/12 MET Ex14Δ ); 2 had PD (2/12 MET Ex14Δ ); and 2 were not evaluable. 10 NSCLC pts were MET TKI naive (7 MET Amp and 3 MET Ex14Δ ) and had 50% ORR and 100% DCR (5 PR and 5 SD; DoR range 1 to 18.3 m; DoE 1.5 to 22 m); 10 NSCLC pts were prior MET TKI treated (9 MET Ex14Δ and 1 MET Amp+Ex14Δ ) with DCR 60%, (6 SD; DoE 0.4-9.6 m). Median PFS was 5.5 m overall (95% CI 3.5-9.7 m). Median PFS for MET TKI naive and MET TKI pre-treated NSCLC pts was 6.5 m (95% CI 3.4-21.9 m) and 5.4 m (95% CI 1.2-9.7 m) respectively. Median OS was not reached for overall or for prior MET TKI subgroups. 89% MET Ex14 ∆ tumor tissue to blood concordance (8/9 NSCLC pts) was observed. Conclusions: Sym015 was well-tolerated at the RP2D with a response rate similar to MET TKI in MET-treatment naïve MET Amp/Ex14Δ NSCLC and seems to delay disease progression in MET TKI pretreated NSCLC pts. Combination with MET TKI to delay or prevent resistance should be further explored. Clinical trial information: NCT02648724 .
Emotional distress, stress, and cardiovascular health in adult survivors of childhood cancer.
Authors: Margaret M. Lubas, Mingjuan Wang, John L. Jefferies, Kirsten K. Ness, Matthew J. Ehrhardt, Kevin R. Krull, Daniel A. Mulrooney, Deo Kumar Srivastava, Leslie L. Robison, Melissa M. Hudson, Gregory T. Armstrong, Tara M. Brinkman
Journal: Journal of Clinical Oncology (2020)

10547 Background: The contribution of emotional distress and stress to cardiac health in adult survivors of childhood cancer has not been reported, despite evidence of causal associations in the general population. Methods: Comprehensive medical assessments and standardized measures of depression, anxiety, post-traumatic stress disorder, and perceived stress were performed on 3,267 survivors in the St. Jude Lifetime Cohort (median[range] 29.9[18.0-64.5] years of age; 7.7[0-24.8] years at diagnosis; 49% female). Physical outcomes included hypertension, diabetes, dyslipidemia, cardiomyopathy, dysrhythmia (grades 2-4 per the NCI CTCAE criteria), myocardial infarction (grades 3-4), and metabolic syndrome (yes/no). Multivariable generalized linear models examined associations between these outcomes with any distress/stress, adjusted for demographics, cumulative anthracycline dose and thoracic radiation, physical activity, BMI, smoking, and alcohol intake. Unadjusted longitudinal associations between distress/stress and new onset cardiac conditions were examined among survivors who completed repeat medical assessment(s) (n = 1748; median follow-up = 3.9 years). New onset conditions were defined as a change from grade 0-1 at baseline to ≥ grade 2 at follow-up. Results: Survivor reported distress/stress (29% overall) was more prevalent in those with hypertension (28.2% vs 19.5%, P&lt; 0.001), dyslipidemia (16.4% vs. 11.3%, P&lt; 0.001), diabetes (9.4% vs. 6.9%, P= 0.02), and metabolic syndrome (32.2% vs. 23.2%, P&lt; 0.001), but not among dysrhythmia, cardiomyopathy, and myocardial infarction. In separate multivariable models, distress/stress was associated with hypertension (RR = 1.24, 95% CI 1.07-1.43), dyslipidemia (RR = 1.29, 95% CI 1.03-1.61), and metabolic syndrome (RR = 1.35, 95% CI 1.17-1.54). Baseline distress/stress was associated with new onset hypertension (OR = 1.33, 95% CI 0.94-2.01), dyslipidemia (OR = 1.37, 95% CI 0.94-1.87), and dysrhythmia (OR = 2.78, 95% CI 1.12-6.91). Conclusions: Emotional distress/stress is associated with adverse cardiovascular health and may serve as an intervention target for improving cardiac health outcomes among survivors of childhood cancer.
Anaplastic lymphoma kinase (ALK) partners identified by next-generation sequencing in Chinese patients with solid tumors.
Authors: Sheng Yang, Fuyu Gong, Guoqiang Wang, Xiaohui He
Journal: Journal of Clinical Oncology (2020)

3555 Background: Anaplastic lymphoma kinase (ALK) rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC). More than 30 different fusion partner genes of ALK in NSCLC have been reportedand most of these ALK fusions respond well to ALK inhibitors crizotinib. With the development of next-generation sequencing (NGS), more novel partners for ALK rearrangement have been identified. Here, we aimed to report the landscape of ALK rearrangement in Chinese patients with solid tumors. Methods: Tissue or blood samples were subjected to NGS in a College of American Pathologists-certified and Clinical Laboratory Improvement Amendments-accredited lab for ALK arrangement. Results: In total, we profiled more than 40,000 patients, among which 72 cases with 52 ALK fusion partner, harboring 17 reported partners and 35 novel partners. The average ALK rearrangement patients' age was 53 years (range, 17-76 years). Among all the ALK fusion cases (n = 72), lung cancer were the largest proportion with 77.8% (n = 56), colorectal cancer accounted for, 5.5% (n = 4), liver cancer accounted for 4.2% (n = 3), biliary cancer, melanoma, carcinosarcoma and inflammatory myofibroblastic tumor accounted for 2.8% (n = 2) respectively, and only one case (n = 1) was malignant peritoneal mesothelioma. The most common ALK fusion partners were KIF5B (n = 6), DCTN1 (n = 5) and STRN (n = 5). In 38 cases, 35 novel ALK fusion partners were discovered. The novel CLIP4-ALK, EHBP1-ALK, PLB1-ALK occurred twice in 6 patients, which were two lung cancer patients with CLIP4-ALK fusion, two lung cancer patients with PLB1-ALK fusion, one hepatic cellular cancer patients with EHBP1-ALK, and one melanoma patients with EHBP1-ALK. There were two special lung cancer cases with two ALK fusions. One case detected the novel LRIG1-ALK fusion and novel PLB1-ALK fusion, the other case detected novel GLI3-ALK fusion and reported HIP1-ALK fusion. Conclusions: Novel ALK fusions are detected in patients with not only NSCLC but also other solid tumors. NGS fusion assay is an optional method for screening novel fusions.
Risk factors of hyperamylasemia in diabetic ketoacidosis
Authors: Jian-jia Jiang, Jin-bo Su, Wen-sen Huang, Fang He, Wei-min He, Chun-tuan Li
Journal: BMJ (2008)

Risk factors of hyperamylasemia in 152 diabetic ketoacidosis(DKA)patients who had no acute pancreatitis were examined.Serum levels of hemodiastase,natrium,kalium,chlorine,calcium,phosphonium,creatinine,carbon dioxide combining power,osmotic pressure,blood glucose,blood lipids and uric acid were measured.With hemodiastase and other 14 factors as independent variables,the multiple linear regression analysis was performed and the partial regression coefficient was estimated.Blood glucose,serum natrium,osmotic pressure and triglyceride entered the regression equation,and their partial coefficients were 10.26,10.35,2.21 and 8.00,respectively.The constant quantitv was -2162.06.Compared with amylase-normal group,hyperamylasemia group showed statistically significant difference in blood glucose,serum natrium,osmotic pressure and triglyceride levels.Higher blood glucose and triglyceride might be the primary causes of hyperamylasemia.

Key words: 
Diabetic ketoacidosis;  Amylases
口腔溃疡-多饮-全身多发溃疡
Authors: 彭琳一, 费允云, 庄俊玲, 张文, 张奉春
Journal: BMJ (2012)

患者男,55岁,因反复口腔溃疡35年,双耳溢脓12年,全身多发溃疡3年于2011年2月入本院治疗.35年前患者无明显诱因出现反复口腔溃疡,每3～5个月出现一次;15年前口腔溃疡加重,发作频繁,每2周发生一次;12年前出现双耳脓性分泌物,听力逐渐下降;8年前出现牙齿片状脱落,至今仅剩右上一颗磨牙;3年前反复出现肛周溃疡,伴有双侧腹股沟皮疹、瘙痒,遂渐出现双侧腹股沟溃疡,肚脐脓性分泌物,未诊治;1年前出现唇周及鼻尖处瘙痒性皮疹,后逐渐出现双俐口角溃疡. 关键词：组织细胞增多症;朗格尔汉斯细胞
Development of clinical pathways and two-way referral system for type 2 diabetes in an urban community
Authors: 梁万年, 曹红霞, 路孝琴, 彭小霞, 刘民, 杜雪平, 周海虹, 王海燕, 李亚玉, 庄晓明, 李雅媛, 侯武姿, 戴秋颖, 乌正赉
Journal: BMJ (2005)

目的 开发设计适合我国城市社区人群2型糖尿病诊治的临床路径.方法采用文献法、专家会议法、现场考察和预试验的方法,研制中国城市社区人群的2型糖尿病诊治的临床路径.结果建立了2型糖尿病的社区照顾路径、酮症酸中毒专科诊疗路径、低血糖症患者专科诊疗路径、2型糖尿病患者社区-专科双向转诊技术路径和管理路径、单纯2型糖尿病患者专科诊疗路径.结论 2型糖尿病诊治的临床路径是以循证医学为指导,在强调诊疗服务标准化的同时,突出了全科医学连续性照顾的特点。
Development and evaluation of patient reported outcomes-based performance measures during chemotherapy.
Authors: Benjamin Urick, Angela M. Stover, Allison Mary Deal, Jennifer Jansen, Anne C. Chiang, Charles S. Cleeland, Dylan M. Zylla, Ethan M. Basch
Journal: Journal of Clinical Oncology (2020)

e19175 Background: As value-based oncology care models become increasingly common, there is need for reliable and valid patient-reported outcome performance measures (PRO-PMs) to assess quality of symptom control at practices. We propose a method for combining PRO items across multiple symptoms into a single reliable and valid summary PRO-PM metric. Methods: Symptom surveys were administered to 607 patients at 6 cancer centers, between 5-15 days after starting a chemotherapy cycle. Twelve symptoms were elicited, each scored from 0-4, with higher scores indicating greater severity. Summary PRO-PM metrics were generated by summing scores for symptoms. A 3-item short form (score range 0-12) included nausea, diarrhea, and pain. A 12-item long form (score range 0-48) included short form items plus neuropathy, dyspnea, vomiting, fatigue, constipation, anxiety, sadness, insomnia, and appetite. PRO-PM summary item scores were dichotomized into high and low symptom burden categories. Cut points for dichotomization were compared based on reliability, validity, and prevalence. Reliability was defined as the average of practice-specific signal-to-noise ratios, with an optimal score ≥0.7. Practice-level validity was defined as the Pearson correlation between the proportion of patients with high symptom burden and low self-reported physical functioning. Patient-level validity was estimated as the relative risk (RR) of low physical functioning for patients with high vs. low symptom burden. For prevalence, measures were required to have &gt; 5% or &lt; 95% of patients with high symptom burden. Optimal cut-points were identified via a scatter plot comparing measure reliability and validity. Results: Optimal cut-points were identified for both summary PRO-PM metrics. For the short form, a cut-point at ≥5 had a reliability of 0.56, correlation of 0.14, RR of 2.56, and prevalence of 24.5%. For the long form, a cut point at ≥22 had reliability of 0.54, correlation of 0.56, RR of 2.61, and prevalence of 8.5%. Conclusions: Summary PRO-PM metrics can be generated from multiple PRO symptom items, with optimal cut-point scores determined by comparing reliability and validity. Reliability scores approached but did not meet the recommended 0.7 threshold due to sample size, therefore additional data are currently being collected to further support these cut points.
Serum S-100 protein levels in children with Henoch-Schonlein syndrome and its clinical significance
Authors: Yuan Lei, Yue Huang, Jianjun Wang, Zengrong Liu, Jie Yang, Xiaojiang Lyu, Li Qin
Journal: BMJ (2017)

Seventy eight children with Henoch-Schonlein syndrome (HSP) admitted in our hospital from October 2013 to April 2015 were enrolled in this study, and 30 healthy children were also enrolled as controls. The serum S-100 protein levels were measured with enzyme-linked immunosorbent assay (ELISA) in two groups; and electroencephalogram (EEG) examination was performed in HSP patients. The serum S-100 protein level of HSP group (0.206±0.101) μg/L was significantly higher than that in the normal control group [(0.060±0.042) μg/L, P<0.001]; and the serum S-100 protein levels in patients with kidney type (0.284±0.099) μg/L and mixed type [(0.284±0.043) μg/L, P<0.01] were higher than those in patients with skin type (0.151±0.098) μg/L, gastrointestinal type (0.138±0.036) μg/L and joint type [(0.117±0.065) μg/L, P<0.001]. Abnormal EEG findings were detected in 52 cases (66.7%), however, no clinical manifestations of nervous system were found in those patients. Serum S-100 protein levels were higher in patients with abnormal EEG than those with normal EEG [(0.223±0.099) μg/L vs. (0.173±0.096) μg/L, P<0.05]. The results suggest that the serum S-100 protein is associated with HSP disease severity, and children with HSP may have subclinical neurological damage.


Key words: 
Schonlein-Henoch; S100 Protein; Child
静脉注射有机磷农药中毒抢救成功一例
Authors: 何敬之, 何敬堂
Journal: BMJ (2009)

患者女,2007年5月10日与家人生气后自行静脉推注乐果40 ml,10 min后被发现.患者意识模糊、尖叫、口吐白沫,无四肢抽搐和大小便失禁.1 h后送入我院.查体:体温35.4℃,呼吸16次/min,脉搏70次/min,血压90/60mm Hg(1 mm Hg=0.133 kPa),神志恍惚,呼唤反应迟钝,皮肤潮湿、微汗,双侧瞳孔直径1 mm,对光反射迟钝,口腔内白色泡沫状分泌物,口唇稍紫绀,双肺中下细湿哕音,心律齐,心音低钝,未闻杂音,胆碱酯酶1.6 kU/L(正常值3.5～12.0 kU/L)。
Breast cancer screening in primary care facilities: what we should pay attention to?
Authors: Xiaofeng Bi, Zhongzhao Wang, Lixue Xuan
Journal: BMJ (2017)

乳腺癌发病率的不断上升使乳腺癌的预防工作日益受到重视，而有效的乳腺癌的筛查可以降低其发病率和死亡率。基层乳腺癌筛查工作还存在着一些困扰，本文就乳腺癌筛查的方法、乳腺癌筛查年龄和间隔的问题以及基层医生培训和群众科学认知等问题做一评述，讨论如何有效地在基层开展乳腺癌筛查工作，提高基层乳腺癌防控工作的效果。
前立腺癌に関するEAUガイドライン パートII:進行性再発性および性腺摘除抵抗性前立腺癌の治療
Authors: Mottet Nicolas, Bellmunt Joaquim, Bolla Michel, Joniau Steven, Mason Malcolm, Matveev Vsevolod, Schmid Hans-Peter, Van Der Kwast Theo, Wiegel Thomas, Zattoni Filiberto, Heidenreich Axel
Journal: European Urology (2011)
Effect of urokinase gene knockout and chronic neurogenic pain on melanoma growth in the experiment.
Authors: Irina V. Kaplieva, Elena M. Frantsiyants, Ekaterina I. Surikova, Irina V. Neskubina, Valeria A. Bandovkina, Lidia K. Trepitaki, Natalia S. Lesovaya, Natalia D. Cheryarina, Ludmila A. Nemashkalova, Viktoria V. Pozdnyakova, Yuriy V. Przhedetskiy, Natalia A. Zakharova, Olga V. Khokhlova, Viktoria Yu. Przhedetskaya, Oleg I. Kit
Journal: Journal of Clinical Oncology (2020)

e22099 Background: Studies have shown that the axis of the urokinase-type plasminogen activator (uPA–uPAR) has a pleiotropic effect in different stages of cancer. The purpose of the study was to reveal characteristics of the B16/F10 melanoma development in mice with the uPA gene knockout with and without chronic neurogenic pain (CNP). Methods: The study included male and female С57ВL/6 mice (n = 102) and C57BL/6-Plautm1.1BugThisPlauGFDhu/GFDhu mice with the uPA gene knockout (n = 48). B16/F10 melanoma was transplanted subcutaneously to the animals in the main groups 2 weeks after bilateral sciatic nerve ligation (CNP model). Mice with the standard melanoma transplantation were the controls. Results: The survival of uPA gene-knockout mice with melanoma was similar to that in controls and was 1.5 times (p &lt; 0.05) longer in females than in males; the melanoma onset in these mice was observed a week earlier; the dynamics of tumor growth showed a pronounced gender dependence: in females, the tumor practically did not grow, and its volume before the death did not exceed 1.0 cm 3 , while in males the tumor was characterized by an active growth with two peaks of the volume increase (weeks 2 and 4); melanoma metastasized weakly - single metastases to the lungs (in females) or no metastases but with hemorrhages in the lungs and heart (in males). CNP reduced the survival of uPA gene-knockout females, similar to mice with the normal genome, but did not affect the survival of males; primary tumors in uPA gene-knockout mice emerged a few days later than in the control, but grew more intensively, with gender differences smoothed out; increased metastasis was demonstrated by the initiation of metastatic lesions of the lungs and liver in males, while hemorrhages in the lungs maintained, and by an increased number of metastases in the lungs with the appearance of lung hemorrhages in females. Conclusions: The uPA gene knockout differently changes the course of B16/F10 melanoma in male and female mice. CNP enhances the tumor growth, erasing gender differences, and activates metastasis of melanoma.
Effect on response to neoadjuvant chemotherapy in high-grade serous ovarian cancer by inhibiting the GAS6/AXL pathway and inducing homologous recombination deficiency.
Authors: Mary M Mullen, Elena Lomonosova, Michael Driscoll Toboni, Hollie M Noia, Danny Wilke, Alyssa Oplt, Lei Guo, Lindsay M Kuroki, Andrea R. Hagemann, Carolyn K McCourt, Premal H. Thaker, David Gardner Mutch, Matthew A. Powell, Katherine Cynthia Fuh
Journal: Journal of Clinical Oncology (2020)

6080 Background: Less than 10% of patients with high grade serous ovarian cancer (HGSC) have a complete pathologic response to neoadjuvant chemotherapy. We aimed to identify a biomarker predictive of response to neoadjuvant chemotherapy and to determine if GAS6/AXL inhibition with AVB500 (AVB) could increase platinum response. Methods: AVB was supplied by Aravive Biologics. HGSC tumor samples were obtained pre- and post-neoadjuvant chemotherapy. GAS6 expression was measured by tissue immunohistochemistry (IHC) and serum ELISA. Four HGSC cell lines were used for all experiments. Immunofluorescent (IF) assays targeting ɣH2AX for DNA damage, RAD51, BRCA1, and BRCA2 for homologous recombination (HR) and 53BP1 for non-homologous end joining (NHEJ) were performed. Flow cytometry was used to evaluate RPA binding. DNA fiber assays were performed. In vitro clonogenic assays were done on chemoresistant ovarian tumor cells treated with carboplatin (carbo) +/- AVB and olaparib +/- AVB. Synergy assays were analyzed using Combenefit software. Mouse models were used to evaluate the combination of carboplatin + AVB and olaparib + AVB on tumor burden. Results: Patients with high pretreatment tumor GAS6 IHC expression ( &gt; 85%) or serum GAS6 concentrations ( &gt; 25ng/mL) were more likely to have a poor response to neoadjuvant chemotherapy than those with low GAS6 (P = 0.002). Additionally, high GAS6 concentration was associated with decreased overall survival (24.4 months versus undefined, P = 0.009). Carbo + AVB resulted in decreased clonogenic colonies compared to carbo alone (p &lt; 0.05). In vivo tumor mouse models treated with chemotherapy + AVB had significantly less tumor burden than those treated with chemotherapy alone (50mg vs 357mg, P = 0.003). We identified an induction in HR deficiency by a decrease in RAD51, BRCA1, and BRCA2 foci and RPA binding in cells treated with carbo + AVB compared to carbo (P &lt; 0.05). There was increase in ɣH2AX and 53BP1 foci as well as replication fork slowing in tumor cells treated with carboplatin + AVB (P &lt; 0.01). We also AVB and carboplatin were synergistic. Olaparib + AVB resulted in decreased clonogenic colonies (P &lt; 0.05) and decreased tumor burden in mouse models (76mg vs 171mg, P = 0.03) compared to olaparib alone. Conclusions: GAS6 is a potential biomarker predictive of poor response to neoadjuvant chemotherapy in HGSC. Inhibition of this GAS6/AXL pathway with AVB improves sensitivity to traditional neoadjuvant chemotherapy by inducing a homologous recombination deficiency.